- Home
- BKTI vs VCRE Comparison
BKTI vs VCRE Comparison
Compare BKTI & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BKTI | VCRE |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.1M | 271.7M |
| IPO Year | 2000 | 2026 |
Fundamental Metrics
Financial Performance| Metric | BKTI | VCRE |
|---|---|---|
| Price | $68.00 | $9.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $29.16 |
| AVG Volume (30 Days) | ★ 39.4K | 25.1K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.89 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $74,094,000.00 | N/A |
| Revenue This Year | $4.72 | $101.29 |
| Revenue Next Year | $14.74 | $481.15 |
| P/E Ratio | $44.23 | ★ N/A |
| Revenue Growth | ★ 45.42 | N/A |
| 52 Week Low | $60.00 | $7.88 |
| 52 Week High | $104.55 | $14.01 |
Technical Indicators
Market Signals| Indicator | BKTI | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 39.64 |
| Support Level | N/A | $8.34 |
| Resistance Level | $76.13 | $12.08 |
| Average True Range (ATR) | 2.25 | 0.80 |
| MACD | -0.89 | 0.03 |
| Stochastic Oscillator | 26.42 | 23.06 |
Price Performance
Historical ComparisonAbout BKTI BK Technologies Corporation
BK Technologies Corp is a holding company that, through BK Technologies, Inc., its operating subsidiary, provides public safety-grade communications products and services designed to make first responders safer and more efficient. All operating activities described herein are undertaken by its operating subsidiary. The Company has one reportable segment - Land Mobile Radio (LMR) Products and Solutions. The LMR segment provides radio devices that are hand-held (portable) or installed in vehicles (mobile) and operate on private radio systems that are P25 compliant. The Company derives revenue in North America and manages the business activities on a consolidated basis.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.